EUVIMEDEUVIMED entdecken
Crossref

Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients

Dimo Dietrich, Simone Weider, Luka de Vos, Timo Jakob Vogt, Moritz Färber, Romina Zarbl, Alina Hunecke, Ann-Kathrin Glosch, Jennis Gabrielpillai, Friedrich Bootz, Franz-Georg Bauernfeind, Franz-Josef Kramer und 4 weitere

Clinical Chemistry · 01.09.2023 · 69 (9) · 1050-1061

DOI: 10.1093/clinchem/hvad084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Chemistry, online erschienen am 21.07.2023. Verfasst von Dimo Dietrich und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, University Medical Center Bonn (UKB), Bonn, Germany. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Cell-Free Nucleic Acids, Head and Neck Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tumorous SEPT9 (septin 9, SEPTIN9) circulating cell-free DNA (ccfDNA) methylation in blood plasma is a powerful biomarker for diagnosis, molecular staging, prognosis, and recurrence monitoring in head and neck squamous cell carcinoma (HNSCC) patients. The present study aimed to evaluate the clinical performance of SEPT9 ccfDNA methylation to detect post-surgical minimal residual disease (MRD) in patients with localized or locally advanced HNSCC treated with curative intent.

Methods

We applied quasi-digital methylation-specific real-time PCR to quantify SEPT9 ccfDNA methylation levels 2 to 30 days post-surgically in plasma from n = 219 prospectively enrolled HNSCC patients. We tested the associations of SEPT9 ccfDNA methylation with clinicopathological parameters and used Kaplan–Meier and Cox proportional hazards analyses for univariate, pairwise bivariate, and multivariate analyses of disease-free survival.

Results

Of 219 patients, 26.5% (58/219) were post-surgically SEPT9 ccfDNA methylation positive. SEPT9 ccfDNA methylation positivity was significantly associated with tumor site, American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC; 8th edition) tumor stage, nodal category and extracapsular extension, lymphatic and vascular invasion, and surgical margin. Bivariate Cox proportional hazards analysis proved post-surgical SEPT9 ccfDNA methylation positivity to be an independent prognostic factor tested together with AJCC/UICC tumor stage (SEPT9: hazard ratio [HR] = 2.43, 95% CI, 1.37–4.30, P = 0.002; AJCC/UICC stage: HR = 1.48, 95% CI, 1.11–1.98, P = 0.008).

Conclusions

Post-surgical SEPT9 ccfDNA methylation may aid to identify high-risk HNSCC patients who could benefit from an intensified adjuvant treatment and surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellCell-Free Nucleic AcidsHead and Neck NeoplasmsHumansBiomarkers, TumorCytoskeletal ProteinsDNA MethylationHomeodomain ProteinsNeoplasm StagingNeoplasm, ResidualPrognosisSquamous Cell Carcinoma of Head and NeckSeptins

Substanzen

Biomarkers, TumorCell-Free Nucleic AcidsCytoskeletal ProteinsHomeodomain ProteinsSEPTIN9 protein, humanSeptins

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, University Medical Center Bonn (UKB), Bonn, Germany.
  • Department of Oral and Maxillofacial Surgery, University Medical Center Bonn (UKB), Bonn, Germany.
  • Department of Dermatology and Allergology, University Medical Center Bonn (UKB), Bonn, Germany.
  • Department of Oncology, Hematology and Rheumatology, University Medical Center Bonn (UKB), Bonn, Germany.
  • Department of Pathology, University Medical Center Bonn (UKB), Bonn, Germany.

ORCID-Profile: Alina Franzen

Zitieren

APA

Dietrich, D., Weider, S., de Vos, L., Vogt, T. J., Färber, M., Zarbl, R., Hunecke, A., Glosch, A. K., Gabrielpillai, J., Bootz, F., Bauernfeind, F. G., Kramer, F. J., Kristiansen, G., Brossart, P., Strieth, S., & Franzen, A. (2023). Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients. Clinical Chemistry, 69(9), 1050-1061. https://doi.org/10.1093/clinchem/hvad084

Vancouver

Dietrich D, Weider S, de Vos L, Vogt TJ, Färber M, Zarbl R, et al. Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients. Clinical Chemistry. 2023;69(9):1050-1061. doi:10.1093/clinchem/hvad084

BibTeX
@article{Dietrich2023,
  author = {Dietrich, Dimo and Weider, Simone and de Vos, Luka and Vogt, Timo Jakob and Färber, Moritz and Zarbl, Romina and Hunecke, Alina and Glosch, Ann-Kathrin and Gabrielpillai, Jennis and Bootz, Friedrich and Bauernfeind, Franz-Georg and Kramer, Franz-Josef and Kristiansen, Glen and Brossart, Peter and Strieth, Sebastian and Franzen, Alina},
  title = {Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients},
  journal = {Clinical Chemistry},
  year = {2023},
  volume = {69},
  number = {9},
  pages = {1050--1061},
  doi = {10.1093/clinchem/hvad084}
}
Kostenlos starten →